Omega Advisors’s Esperion Therapeutics ESPR Stock Holding History

Omega Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-25,000	Closed	-$2.31M	–	107
2015 Q1	$2.31M	Buy	+25,000	New	+$1.61M	0.04%	88

Other funds holding ESPR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Omega Advisors's ESPR Position: Q2 2015 in Review

Omega Advisors sold out of Esperion Therapeutics (ESPR) in Q2 2015, closing a stake of 25,000 shares — an estimated $2.31M sold.

Omega Advisors first reported a position in ESPR in Q1 2015 and held it in 1 quarter. The position peaked at $2.31M in Q1 2015. 151 funds tracked by Wall St. Rank hold ESPR as of Q2 2015.

Omega Advisors reported no remaining Esperion Therapeutics position as of Q2 2015 after selling out during the quarter.
Omega Advisors sold 25,000 Esperion Therapeutics shares in Q2 2015, an estimated $2.31M.
Omega Advisors first reported a position in Esperion Therapeutics in Q1 2015 and held it in 1 quarter.
Omega Advisors's Esperion Therapeutics position peaked at $2.31M in Q1 2015.
151 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2015.

Based on Omega Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.